CTNM Stock Price | Contineum Therapeutics, Inc. Class A Common Stock P/E, Revenue, EPS, & Forecasts

Contineum Therapeutics, Inc. Class A Common Stock • CTNM

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Contineum Therapeutics, Inc. Class A Common Stock

Ticker

CTNM

Trading on

NASDAQ

ISIN

US21217B1008

Industry

Biotechnology

Sector

Healthcare

CEO

Carmine N. Stengone MBA, MS

Headquarters

3565 General Atomics Court, San Diego, CA, United States, 92121

Employees

Website

contineum-tx.com

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Metrics

BasicAdvanced

Market cap

$103M

P/E ratio

EPS

-$2.49

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-58.8M

Ex dividend date

Price & volume

Market cap

$103M

Average daily volume

0.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

11.15

Price to book

0.56

Earnings

EPS

-$2.49

EPS estimate (current quarter)

-$0.57

EPS estimate (next quarter)

-$0.37

EBITDA

$-58.8M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

52-week High

$21.92

52-week Low

$3.35

50-day moving average

$4.18

200-day moving average

$10.46

Short ratio

6.13

Short %

4.56%

Management effectiveness

ROE (TTM)

-33.03%

ROA (TTM)

-22.95%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

19.1M

Float

13.2M

Insiders %

1.82%

Institutions %

79.99%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 5 analysts.

Average price target

$23.71

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.39

-$0.35

-11.43%

Q2 • 24Missed

-$0.40

-$0.41

2.44%

Q3 • 24Beat

-$0.56

-$0.43

-30.23%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0.2M

$-14.6M

-6,018.60%

Q4 • 24

$0M

$-16M

-∞%

Q1 • 25

-100.00%

9.78%

∞%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$213M

$14.8M

6.94%

Q4 • 24

$198M

$13.5M

6.81%

Q1 • 25

-6.85%

-8.69%

-1.98%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-10.2M

$-9.4M

$0.6M

$-10.4M

Q4 • 24

$-14.4M

$14.9M

$0M

$-14.5M

Q1 • 25

41.27%

-258.87%

-96.26%

39.46%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Contineum Therapeutics, Inc. Class A Common Stock share?

Contineum Therapeutics, Inc. Class A Common Stock shares are currently traded for undefined per share.

How many shares does Contineum Therapeutics, Inc. Class A Common Stock have?

Contineum Therapeutics, Inc. Class A Common Stock currently has 19.1M shares.

Does Contineum Therapeutics, Inc. Class A Common Stock pay dividends?

No, Contineum Therapeutics, Inc. Class A Common Stock doesn't pay dividends.

What is Contineum Therapeutics, Inc. Class A Common Stock 52 week high?

Contineum Therapeutics, Inc. Class A Common Stock 52 week high is $21.92.

What is Contineum Therapeutics, Inc. Class A Common Stock 52 week low?

Contineum Therapeutics, Inc. Class A Common Stock 52 week low is $3.35.

What is the 200-day moving average of Contineum Therapeutics, Inc. Class A Common Stock?

Contineum Therapeutics, Inc. Class A Common Stock 200-day moving average is $10.46.

Who is Contineum Therapeutics, Inc. Class A Common Stock CEO?

The CEO of Contineum Therapeutics, Inc. Class A Common Stock is Carmine N. Stengone MBA, MS.

How many employees Contineum Therapeutics, Inc. Class A Common Stock has?

Contineum Therapeutics, Inc. Class A Common Stock has 41 employees.

What is the market cap of Contineum Therapeutics, Inc. Class A Common Stock?

The market cap of Contineum Therapeutics, Inc. Class A Common Stock is $103M.

What is the P/E of Contineum Therapeutics, Inc. Class A Common Stock?

The current P/E of Contineum Therapeutics, Inc. Class A Common Stock is null.

What is the EPS of Contineum Therapeutics, Inc. Class A Common Stock?

The EPS of Contineum Therapeutics, Inc. Class A Common Stock is -$2.49.

What is the PEG Ratio of Contineum Therapeutics, Inc. Class A Common Stock?

The PEG Ratio of Contineum Therapeutics, Inc. Class A Common Stock is null.

What do analysts say about Contineum Therapeutics, Inc. Class A Common Stock?

According to the analysts Contineum Therapeutics, Inc. Class A Common Stock is considered a buy.